MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock, net of...
$668,438K
Proceeds from the
exercise of stock options
$430K
Net cash provided by
financing activities
$667,026K
Canceled cashflow
$1,842K
Net decrease in
cash, cash...
$18,475K
Canceled cashflow
$648,551K
Payments of deferred
offering costs related to...
$1,842K
Maturities of marketable
securities
$118,787K
Accrued expenses and
other current...
$15,054K
Accounts payable
$12,338K
Stock-based compensation
expense
$8,344K
Other non-current
assets
-$2,289K
Non-cash lease expense
-$272K
Depreciation and
amortization expense
$101K
Other
-$8K
Net cash used in
investing activities
-$571,024K
Net cash used in
operating activities
-$77,527K
Canceled cashflow
$118,787K
Canceled cashflow
$38,406K
Purchases of marketable
securities
$689,811K
Net loss
-$111,307K
Accretion of discounts on
investments, net
$1,667K
Non-current clinical
deposits
$1,353K
Prepaid expenses and
other current assets
$1,285K
Operating lease
liabilities
-$255K
Other non-current
liabilities
-$66K
Back
Back
Cash Flow
Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics, Inc. (KLRA)
source: myfinsight.com